Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Gains from Sales and Divestitures (2021 - 2025)

BioAtla (BCAB) has disclosed Gains from Sales and Divestitures for 5 consecutive years, with $728295.0 as the latest value for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 634.88% year-over-year to $728295.0; the TTM value through Dec 2025 reached $728295.0, up 634.88%, while the annual FY2025 figure was $728295.0, 634.88% up from the prior year.
  • Gains from Sales and Divestitures hit $728295.0 in Q4 2025 for BioAtla, up from $644995.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $944991.0 in Q4 2021 and bottomed at $37062.0 in Q1 2024.
  • Average Gains from Sales and Divestitures over 5 years is $310065.6, with a median of $238131.0 recorded in 2023.
  • Year-over-year, Gains from Sales and Divestitures plummeted 89.85% in 2023 and then surged 880.79% in 2025.
  • BioAtla's Gains from Sales and Divestitures stood at $944991.0 in 2021, then plummeted by 52.78% to $446260.0 in 2022, then tumbled by 89.85% to $45290.0 in 2023, then skyrocketed by 118.82% to $99104.0 in 2024, then surged by 634.88% to $728295.0 in 2025.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $728295.0, $644995.0, and $561482.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.